Cover Image
市場調查報告書

胃癌治療藥市場分析·預測

Gastric Cancer Forecast and Market Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 603939
出版日期 內容資訊 英文 334 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
胃癌治療藥市場分析·預測 Gastric Cancer Forecast and Market Analysis to 2024
出版日期: 2017年12月11日 內容資訊: 英文 334 Pages
簡介

本報告提供胃癌治療藥市場相關調查分析,市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等,提供著有系統的資訊。

預測:胃癌治療藥 (2017年12月22日出版)

  • 摘要整理
  • 最新預測更新
  • 市場動態
  • 預測·未來趨勢
  • 市場定義·調查手法
  • 參考資料
  • 產品簡介:ABRAXANE
  • 產品簡介 (後期階段):BAVENCIO
  • 產品簡介:CYRAMZA
  • 產品簡介:HERCEPTIN
  • 產品簡介:KEYTRUDA
  • 產品簡介:OPDIVO
  • 產品簡介 (後期階段):ANDECLAXIMAB
  • 產品簡介 (後期階段):APATINIB

治療:胃癌治療藥 (2017年12月12日出版)

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢

流行病學:美國·日本·EU5個國家的胃癌治療藥 (2017年12月11日出版)

  • 摘要整理
  • 疾病的背景
  • 調查手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制
  • 參考資料
  • 附錄

上市藥:胃癌 (2017年12月22日出版)

  • 摘要整理
  • 產品概要
  • 產品簡介:ABRAXANE
  • 產品簡介:CYRAMZA
  • 產品簡介:HERCEPTIN
  • 產品簡介:KEYTRUDA
  • 產品簡介:OPDIVO
  • 胃癌治療藥的價格·醫療費給付·取得

開發平台:胃癌治療藥 (2017年12月22日出版)

  • 摘要整理
  • 臨床開發平台概要
  • 產品簡介 (後期) :BAVENCIO
  • 產品簡介 (後期) :ANDECLAXIMAB
  • 產品簡介 (後期) :APATINIB
目錄
Product Code: DMKC5561

Disease Overview

Gastric cancer is the second-leading cause of cancer-related mortality worldwide. There is significant geographic variation in the burden of the disease: incidence and mortality are notably high in East Asia, China, Eastern Europe, and Latin America, whereas the disease is no longer as common in North America and Western Europe. Globally, there has been a steady decline in incidence over the past 50 years. This is mostly attributable to the decline in prevalence of H. pylori infections, a decline in tobacco use, and improvements in food preservation and diet.

Market Snapshot

  • The gastric cancer market is projected to reach $2.1bn in value by 2026, with growth driven by immunotherapies.
  • Cyramza plays an important role in the second-line treatment of metastatic and distant relapse gastric cancer.
  • Despite declining incidence proportions, the number of cases is forecasted to increase and prognosis remains poor.
  • Cyramza's dominance in second-line advanced gastric cancer is being challenged as immunotherapies enter the market.
  • Bavencio will target the maintenance setting in order to avoid direct competition with established immunotherapies.
  • Access restrictions are moderate in gastric cancer and GIST.

TABLE OF CONTENTS

FORECAST: GASTRIC CANCER (Published on 22 December 2017)

  • EXECUTIVE SUMMARY
  • RECENT FORECAST UPDATES
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ABRAXANE
  • PRODUCT PROFILE (LATE STAGE): BAVENCIO
  • PRODUCT PROFILE: CYRAMZA
  • PRODUCT PROFILE: HERCEPTIN
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE: OPDIVO
  • PRODUCT PROFILE (LATE STAGE): ANDECLAXIMAB
  • PRODUCT PROFILE (LATE STAGE): APATINIB

TREATMENT: GASTRIC CANCER (Published on 12 December 2017)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: GASTRIC CANCER IN THE US, JAPAN, AND 5EU (Published on 11 December 2017)

  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: GASTRIC CANCER (Published on 22 December 2017)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ABRAXANE
  • PRODUCT PROFILE: CYRAMZA
  • PRODUCT PROFILE: HERCEPTIN
  • PRODUCT PROFILE: KEYTRUDA
  • PRODUCT PROFILE: OPDIVO

GASTRIC CANCER PRICING, REIMBURSEMENT, AND ACCESS (Published on 28 November 2017)

  • GASTRIC CANCER PRICING, REIMBURSEMENT, AND ACCESS

PIPELINE: GASTRIC CANCER (Published on 22 December 2017)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): BAVENCIO
  • PRODUCT PROFILE (LATE STAGE): ANDECLAXIMAB
  • PRODUCT PROFILE (LATE STAGE): APATINIB

LIST OF FIGURES

  • Figure 21: Herceptin for gastric cancer - SWOT analysis
  • Figure 22: Datamonitor Healthcare's drug assessment summary of Herceptin for gastric cancer
  • Figure 23: Datamonitor Healthcare's drug assessment summary of Herceptin for gastric cancer
  • Figure 24: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 25: Keytruda for gastric cancer - SWOT analysis
  • Figure 6: Price sources and calculations, by country
  • Figure 26: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 8: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 29: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 10: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 31: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 32: Apatinib for gastric cancer - SWOT analysis
  • Figure 33: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 34: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 35: Stage distribution of gastric cancer patients, by country
  • Figure 38: Top three regimens used in the adjuvant treatment of Stage III gastric cancer patients, by country
  • Figure 17: Datamonitor Healthcare's drug assessment summary of Keytruda for gastric cancer
  • Figure 18: Datamonitor Healthcare's drug assessment summary of Keytruda for gastric cancer
  • Figure 39: Percentage of Stage IV gastric cancer patients receiving each treatment type, by country
  • Figure 20: Opdivo for gastric cancer - SWOT analysis
  • Figure 40: Percentage of Stage IV gastric cancer patients who progress from first- to second-line therapy or from second- to third-line therapy, by country
  • Figure 41: Top three regimens used for second-line treatment of Stage IV gastric cancer patients, by country
  • Figure 23: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 42: Top three regimens used for first-line treatment of local relapse gastric cancer, by country
  • Figure 25: Datamonitor Healthcare's drug assessment summary of andecaliximab for gastric cancer
  • Figure 26: Datamonitor Healthcare's drug assessment summary of andecaliximab for gastric cancer
  • Figure 27: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 44: Top three regimens used for first-line treatment of distant relapse gastric cancer, by country
  • Figure 29: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 30: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 45: Top three regimens used for second-line treatment of distant relapse gastric cancer, by country
  • Figure 32: Percentage of Stage 0-II gastric cancer patients receiving each type of treatment, by country
  • Figure 47: Abraxane for gastric cancer - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Abraxane for gastric cancer
  • Figure 50: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 51: Cyramza for urothelial bladder cancer - SWOT analysis
  • Figure 37: Percentage of local relapse gastric cancer patients receiving each treatment type, by country
  • Figure 54: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 55: Herceptin for gastric cancer - SWOT analysis
  • Figure 40: Percentage of distant relapse gastric cancer patients receiving each treatment type, by country
  • Figure 58: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 59: Keytruda for gastric cancer - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Keytruda for gastric cancer
  • Figure 44: Trends in incident cases of gastric cancer in the US, Japan, and five major EU markets, 2016-36
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Opdivo for gastric cancer
  • Figure 61: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 63: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 65: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 68: Datamonitor Healthcare's drug assessment summary of andecaliximab for gastric cancer
  • Figure 71: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 72: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 73: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 54: Opdivo for gastric cancer - SWOT analysis
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Opdivo for gastric cancer
  • Figure 56: Datamonitor Healthcare's drug assessment summary of Opdivo for gastric cancer
  • Figure 57: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 58: Bavencio for gastric cancer - SWOT analysis
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 60: Datamonitor Healthcare's drug assessment summary of Bavencio for gastric cancer
  • Figure 61: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 62: Andecaliximab for gastric cancer - SWOT analysis
  • Figure 63: Datamonitor Healthcare's drug assessment summary of andecaliximab for gastric cancer
  • Figure 64: Datamonitor Healthcare's drug assessment summary of andecaliximab for gastric cancer
  • Figure 65: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 66: Apatinib for gastric cancer - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 68: Datamonitor Healthcare's drug assessment summary of apatinib for gastric cancer
  • Figure 69: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: Gastric cancer market value across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: Gastric cancer patient population in the US, Japan, and five major EU markets, by country, 2017-26
  • Table 3: Gastric cancer market value across the US, Japan, and five major EU markets, by class ($m), 2017-26
  • Table 4: Sales of PD-1/PD-L1 inhibitors for gastric cancer across the US, Japan, and five major EU markets, by brand ($m), 2017-26
  • Table 5: Summary of drug classes and molecules included in Datamonitor Healthcare's gastric cancer patient-based forecast
  • Table 6: Exchange rates used for calculating prices
  • Table 7: Patent expiry dates for key marketed brands in gastric cancer across the US, Japan, and five major EU markets, 2017-26
  • Table 8: Estimated launch dates of key pipeline products and marketed brands in gastric cancer across the US, Japan, and five major EU markets, 2017-26
  • Table 9: Medical oncologists and gastroenterologists surveyed for the gastric cancer primary research study, 2017
  • Table 10: Abraxane drug profile
  • Table 11: Abraxane pivotal trial data in gastric cancer
  • Table 32: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 34: Opdivo Phase III trials in gastric cancer
  • Table 14: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 15: Abraxane patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 16: Bavencio drug profile
  • Table 17: Bavencio Phase III trials in gastric cancer
  • Table 18: Bavencio Phase III trial data in gastric cancer
  • Table 19: Bavencio early-phase data in gastric cancer
  • Table 20: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 21: Bavencio patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 22: Cyramza drug profile
  • Table 23: Cyramza pivotal trial data in gastric cancer
  • Table 24: Cyramza sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 25: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 26: Herceptin drug profile
  • Table 27: Herceptin pivotal trial data in gastric cancer
  • Table 28: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 29: Herceptin patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 30: Keytruda drug profile
  • Table 31: Keytruda pivotal trial data in gastric cancer
  • Table 32: Keytruda Phase III trials in gastric cancer
  • Table 33: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 34: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 35: Opdivo drug profile
  • Table 36: Opdivo pivotal trial data in gastric cancer
  • Table 37: Opdivo Phase III trials in gastric cancer
  • Table 38: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 39: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 40: andecaliximab drug profile
  • Table 41: andecaliximab Phase III trials in gastric cancer
  • Table 42: andecaliximab early-phase data in gastric cancer
  • Table 43: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 44: Andecaliximab patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 45: apatinib drug profile
  • Table 46: apatinib Phase III trials in gastric cancer
  • Table 47: apatinib early-phase data in gastric cancer
  • Table 48: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 49: Apatinib patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 50: Medical oncologists and gastroenterologists surveyed for the gastric cancer primary research study, 2017
  • Table 51: Gastric cancer five-year survival rates in the US, by stage at diagnosis
  • Table 52: TNM classification, by stage at diagnosis
  • Table 53: Incident cases of gastric cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 54: Gastric cancer International Statistical Classification of Diseases topography codes
  • Table 55: Cancer registry databases used as a source of gastric cancer incidence data, by country
  • Table 56: Data sources used to segment incident gastric cancer cases by AJCC stage, by country
  • Table 57: Incident cases of gastric cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 58: Age- and gender-specific incident cases of gastric cancer in the US, Japan, and five major EU markets, by country, 2016
  • Table 59: Proportion and number of incident cases of gastric cancer in the US, Japan, and five major EU markets, by AJCC stage at diagnosis and country, 2016
  • Table 60: Proportion and number of incident cases of gastric cancer in the US, Japan, and five major EU markets, by anatomical tumor location and country, 2016
  • Table 74: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 62: Profiled key marketed drugs for gastric cancer
  • Table 63: Abraxane drug profile
  • Table 64: Abraxane pivotal trial data in gastric cancer
  • Table 65: Abraxane sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 66: Abraxane patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 81: Bavencio Phase III trials in gastric cancer
  • Table 68: Cyramza pivotal trial data in gastric cancer
  • Table 83: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 70: Cyramza patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 71: Herceptin drug profile
  • Table 72: Herceptin pivotal trial data in gastric cancer
  • Table 73: Herceptin sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 74: Keytruda drug profile
  • Table 75: Keytruda pivotal trial data in gastric cancer
  • Table 76: Keytruda sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 77: Keytruda patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 78: Opdivo drug profile
  • Table 79: Opdivo pivotal trial data in gastric cancer
  • Table 80: Opdivo Phase III trials in gastric cancer
  • Table 81: Opdivo sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 82: Opdivo patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 83: Profiled pipeline products in development for gastric cancer
  • Table 84: Bavencio drug profile
  • Table 85: Bavencio Phase III trials in gastric cancer
  • Table 86: Bavencio Phase III trial data in gastric cancer
  • Table 87: Bavencio early-phase data in gastric cancer
  • Table 88: Bavencio sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 89: Bavencio patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 90: andecaliximab drug profile
  • Table 91: andecaliximab Phase III trials in gastric cancer
  • Table 92: andecaliximab early-phase data in gastric cancer
  • Table 93: Andecaliximab sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 94: Andecaliximab patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Table 95: apatinib drug profile
  • Table 96: apatinib Phase III trials in gastric cancer
  • Table 97: apatinib early-phase data in gastric cancer
  • Table 98: Apatinib sales for gastric cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 99: Apatinib patient numbers for gastric cancer across the US, Japan, and five major EU markets, by country, 2017-26
Back to Top